Experienced in Chronic Lymphocytic Leukemia (CLL)

Franciane Paul

Montpellier, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Chronic Lymphocytic Leukemia (CLL)
Montpellier, FR 
OverviewLocationsClinical Research

Overview

Franciane Paul practices in Montpellier, France. Paul is rated as an Experienced expert by MediFind in the treatment of Chronic Lymphocytic Leukemia (CLL). Their top areas of expertise are Chronic Graft Versus Host Disease (cGvHD), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant.

Their clinical research consists of co-authoring 28 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Chronic Lymphocytic Leukemia (CLL).

Locations

Montpellier, France
Other Locations
1, Avenue Joliot Curie, Toulouse, 31059, France
Sentaraille, 09190, France
4, Rue Larrey, Angers, 49933, France
Lille, France
Boulevard Laveran, BP 60149, 13384 Marseille Cedex 13, Marseille, 13384, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase I-II Study to Assess Venetoclax + Azacitidine and Donor Lymphocyte Infusion in Patients With MDS or AML in Relapse After Allohematopoietic Stem Cell Transplantation
A Phase I-II Study to Assess Venetoclax + Azacitidine and Donor Lymphocyte Infusion in Patients With MDS or AML in Relapse After Allohematopoietic Stem Cell Transplantation
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Venetoclax, Azacitidine
Study Phase: Phase 1/Phase 2
A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: AG-120
Study Phase: Phase 2
A Prospective, Non-interventional, Multinational Study Evaluating the Efficacy and the Safety of High Dose Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation as a Frontline Therapy for Myeloma Patients With Severe Renal Impairment (IRMYG Study)
A Prospective, Non-interventional, Multinational Study Evaluating the Efficacy and the Safety of High Dose Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation as a Frontline Therapy for Myeloma Patients With Severe Renal Impairment (IRMYG Study)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Other
View 2 Less Clinical Trial

28 Total Publications

Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.
Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.
Journal: The Lancet. Haematology
Published: March 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Paul's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile